USMLE Step 2 CK practice question: Mild asthma (GINA Track 1): as-needed low-dose budesonide-formoterol reliever

USMLE Step 2 CKRespiratoryInternal Medicine

A 24-year-old woman comes to the physician for follow-up of asthma diagnosed 2 years ago. She uses an albuterol inhaler about 3 times per week for cough and chest tightness and wakes at night with symptoms about once per month. She has had no emergency visits or courses of oral glucocorticoids. She takes no other medications and does not smoke. Her inhaler technique is correct. Lung examination shows no wheezing. Spirometry shows an FEV1 of 86% of predicted, with a 14% increase after bronchodilator administration.

According to current GINA recommendations, which of the following is the most appropriate treatment?

  1. Continue as-needed albuterol alone
  2. Daily montelukast with as-needed albuterol
  3. Daily salmeterol with as-needed albuterol
  4. As-needed low-dose budesonide-formoterol
  5. Daily medium-dose fluticasone-salmeterol with as-needed albuterol
Show answer and explanation

Correct answer: D. As-needed low-dose budesonide-formoterol

This patient has mild asthma (symptoms several times a week but on fewer than 4 to 5 days a week, rare night waking, no exacerbations) treated with a short-acting beta2-agonist (SABA) alone. GINA no longer recommends SABA-only treatment for adults or adolescents: even mild asthma involves airway inflammation, and SABA monotherapy is associated with severe exacerbations and asthma death. In GINA's preferred Track 1, steps 1 and 2 use low-dose inhaled glucocorticoid (ICS)-formoterol taken as needed for symptom relief, called an anti-inflammatory reliever. Each inhalation delivers an ICS together with formoterol, a long-acting beta2-agonist with rapid onset, so anti-inflammatory treatment rises exactly when symptoms rise. Compared with a SABA alone, this approach reduces severe exacerbations by more than half; compared with daily low-dose ICS plus a SABA, it gives similar protection with much less total steroid exposure.

If asthma remains uncontrolled, Track 1 escalates to maintenance-and-reliever therapy (MART) with ICS-formoterol, low dose at step 3 and medium dose at step 4. Track 2, the alternative, pairs a SABA reliever with a daily ICS or with an ICS taken whenever the SABA is used. LABA monotherapy without an ICS is never appropriate in asthma.

Why the other options are wrong

  • A. Continue as-needed albuterol alone — SABA-only treatment is no longer recommended for adults or adolescents because it increases the risk of severe exacerbations and asthma death.
  • B. Daily montelukast with as-needed albuterol — Leukotriene receptor antagonists are less effective than ICS and carry a boxed warning for neuropsychiatric effects; they are not preferred.
  • C. Daily salmeterol with as-needed albuterol — LABA monotherapy without an ICS increases the risk of severe exacerbations and asthma-related death.
  • E. Daily medium-dose fluticasone-salmeterol with as-needed albuterol — Daily medium-dose ICS-LABA is step 4 therapy and is excessive for mild asthma.

Key point

For mild asthma in adults and adolescents, GINA's preferred treatment is as-needed low-dose ICS-formoterol rather than a SABA alone.

Memory hook

In GINA, the reliever must also fight inflammation: every puff of budesonide-formoterol brings a steroid along. No SABA solo.

Share: Telegram WhatsApp X LinkedIn

Practice like this every day

15 free bank questions a day, exam-length timed blocks, spaced repetition and 3D anatomy — in English and Russian.

Play free

More free questions in this system

Lambert-Eaton myasthenic syndrome as a paraneoplastic syndrome of small cell lung cancerUSMLE Step 1 · RespiratorySarcoidosis hypercalcemia from macrophage 1-alpha-hydroxylaseUSMLE Step 1 · RespiratoryCarbon monoxide poisoning: oxygen content and dissociation curveUSMLE Step 1 · Respiratory

All free questions →